US Edition
Published • loading... • Updated
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has partnered with NeuroRPM to integrate an FDA-cleared artificial intelligence platform into its ongoing Parkinson’s disease study to improve symptom monitoring and data collection, the company announced. The collaboration will incorporate a wearable, AI-enabled system into Annovis’ open-label Phase 3 study of its investigational therapy buntanetap, which is enrolling patients across 25 U.S. sites ov…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
